1

Procaps Group

#8853

Rank

$113.95M

Marketcap

LU Luxembourg

Country

Procaps Group
Leadership team

Mr. Ruben Minski (Founder, CEO & Chairman)

Dr. Camilo Camacho (Pres)

Mr. Patricio Vargas Munoz (Global Chief Financial Officer)

Products/ Services
Manufacturing, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Luxembourg, Luxembourg, Luxembourg
Established
1977
Company Registration
SEC CIK number: 0001863362
Net Income
20M - 100M
Revenue
100M - 500M
Traded as
PROC
Overview
Location
Summary
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
History

Founded in 2003 as a pharmaceutical manufacturer, Procaps Group has grown over the past decade to become one of the leading global providers of contract manufacturing services for the nutritional, pharmaceutical, and medical device industries. Procaps Group has developed an extensive network of strategically located production, research and development, and distribution facilities throughout Europe, Latin America, and Asia.

Mission
The mission of Procaps Group is to provide quality products and services that benefit our customers, transform and improve their lives, in an efficient and responsible manner.
Vision
Procaps Group’s vision is to be the leading global company providing contract manufacturing services in the nutritional, pharmaceutical and medical device industries, offering innovative and technologically advanced solutions with the highest quality standards.
Key Team

Ms. Melissa Angelini (Investor Relations Director)

Ms. Marcela Carvajalino Pagano (Vice-Pres of Corp. & Legal Affairs)

Mr. Luis Alberto Palacios Aragon (Vice-Pres of International Marketing and R&D)

Mr. Mauricio Castaneda Caballero (Vice-Pres of HR)

Mr. Carlos Piocuda Russo (Head of Optimization of Corp. Value & Corp. VP of Fin.)

Recognition and Awards
Procaps Group has been recognized both regionally and internationally for their commitment to quality and social responsibility. They were named Regional Manufacturer of the Year by the Caribbean Manufacturers Association in 2013, and among the World’s Most Ethical Companies by the Ethisphere Institute in 2014.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Procaps Group
Leadership team

Mr. Ruben Minski (Founder, CEO & Chairman)

Dr. Camilo Camacho (Pres)

Mr. Patricio Vargas Munoz (Global Chief Financial Officer)

Products/ Services
Manufacturing, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Luxembourg, Luxembourg, Luxembourg
Established
1977
Company Registration
SEC CIK number: 0001863362
Net Income
20M - 100M
Revenue
100M - 500M
Traded as
PROC